Abstract
Purpose
Anti-Müllerian hormone has a regulative function in the activation of folliculogenesis and an influence on atresia rate. It is considered a marker for the ovarian reserve. We know that a relationship exists between AMH levels and oocyte retrieval numbers, antral follicle count, pregnancy rates and birth rates. The role of AMH as an efficient prognostic factor in determining the probability of pregnancy has been largely discussed in the literature. The aim of this study is to determine the role age and AMH levels play in success rates of IVF/ICSI therapies. To date, the sample group we examined was one of the biggest ever included in a single study of the subject.
Methods
All patients who underwent an IVF/ICSI treatment with FSH stimulation in the Wiesbaden Kinderwunschzentrum between 2003 and 2010, were no older than 44 years old, and had an evaluation of serum AMH levels before treatment were included in this study. In total, 1287 patients were analysed retrospectively. Statistical analysis was performed with SPSS.
Results
Females’ mean age was 34.89, ranging from 21 to 44 years. The patients underwent between 1 and 11 IVF cycles. Younger women had significantly higher AMH levels (p = 0.001). Patients with higher AMH levels had significantly lower break-off rates (p < 0.0005) and a significantly higher number of oocytes retrieved (p < 0.0005). Higher levels of AMH corresponded to higher pregnancy rates (p = 0.017). AMH levels do not influence pregnancy rates in younger patients (<36 years).
Conclusions
AMH is a useful parameter that should be measured before performing an IVF/ICSI treatment. In younger patients, AMH levels do not predict pregnancy outcomes. In patients older than 36 years, AMH can be used as a prognostic factor. Even when a woman’s AMH levels are too low to be detected, she still an acceptable chance of becoming pregnant.
![](http://media.springernature.com/m312/springer-static/image/art%3A10.1007%2Fs00404-015-3901-0/MediaObjects/404_2015_3901_Fig1_HTML.gif)
Similar content being viewed by others
References
Kelsey TW, Wright P, Nelson SM, Anderson RA, Wallace WH (2011) A validated model of serum anti mullerian hormone from conception to menopause. PLoS One 6(7):e22024. doi:10.1371/journal.pone.0022024
Nelson SM, Messow MC, Wallace AM, Fleming R, McConnachie A (2011) Nomogram for the decline in serum antimullerian hormone: a population study of 9601 infertility patients. Fertil Steril 95:736–741
Jayaprakasan K et al (2012) Prediction of in vitro fertilization outcome at different antral follicle count thresholds in a prospective cohort of 1012 women. Fertil Steril 98(3):657–663
La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC et al (2010) Anti mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). Hum Reprod Update 16(2):113–130
Tsakos E, Tolikas A, Daniilidis A, Asmakopoulos B (2014) Predictive value of anti-müllerian hormone, follicle-stimulating hormone and antral follicle count on the outcomeof ovarian stimulation in women following GnRH-antagonist protocol for IVF/ET. Arch Gynecol Obstet 290:1249–1253
Könninger A, Koch L, Edimiris P, Enekwe A, Nagarajah J, Kasimir-Bauer S et al (2014) Anti-Müllerian hormone: an indicator for the severity of polycystic ovarian syndrome. Arch Gynecol Obstet 290:1023–1030
La Marca A, Malmusi S, Giulini S, Tamaro LF, Orvieto R, Levratti P et al (2004) Anti-Müllerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation. Hum Reprod 19(12):2738–2741
Broer SL et al (2009) The role of antimullerian hormone in prediction of outcome after IVF: comparison with the antral follicle count. Fertil Steril 91(3):705–714
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P (2004) Serum antimullerian hormone/mullerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertil Steril 82:1323–1329
La Marca A, Nelson SM, Sighinolfi G, Manno M, Baraldi E, Roli L et al (2011) Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction. Reprod Biomed Online 22(4):341–349
Lekamge DN et al (2007) Anti-mullerian hormone as a predictor of IVF outcome. Reprod Biomed Online 14(5):602–610
Penarrubia J et al (2005) Basal and stimulation day 5 anti-mullerian hormone serumconcentrations as predictors of ovarian response and pregnancy in assisted reproductive technology cycles stimulated with gonadotropin-releasing hormone agonist—gonadotropin treatment. Hum Reprod 20(4):915–922
Tremellen K, Kolo M (2010) Serum anti-Mullerian hormone is a useful measure of quantitative ovarian reserve but does not predict the chances of live-birth pregnancy. Aust N Z J Obstet Gynaecol 50(6):568–572
Ebner T et al (2006) Basal level of anti-Mullerian hormone is associated with oocyte quality in stimulated cycles. Hum Reprod 21(8):2022–2026
Nelson SM, Yates RW, Fleming R (2007) Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22(9):2414–2421
Iliodromiti S, Kelsey TW, Wu O, Anderson RA, Nelson SM (2014) The predictive accuracy of anti-Mullerian hormone for live birth after assisted conception: a systematic review and meta-analysis of the literature. Hum Reprod Update 20:560–570
van Rooij IA, Bancsi LF, Broekmans FJ, Looman CW, Habbema JD, te Velde ER (2003) Women older than 40 years of age and those with elevated follicle-stimulating hormone levels differ in poor response rate and embryo quality in in vitro fertilization. Fertil Steril 79(3):482–488
Hagen CP, Vestergaard S, Juul A et al (2012) Low concentration of circulation antimüllerian hormone is not predicted of reduced fecundability in young healthy women: a prospective cohort study. Fertil Steril 98(6):1602–1608
Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB (2006) A systematic review of tests predicting ovarian reserve and IVF outcome. Hum Reprod Update 12(6):685–718
Sowers M, McConnell D, Gast K, Zheng H, Nan B, McCarthy JD et al (2010) Anti-Müllerian hormone and inhibin B variability during normal menstrual cycles. Fertil Steril 94(4):1482–1486
Wunder DM et al (2008) Anti-Mullerian hormone and inhibin B as predictors of pregnancy after treatment by in vitro fertilization/intracytoplasmic sperm injection. Fertil Steril 90(6):2203–2210
van Rooij IA et al (2005) Serum antimullerian hormone levels best reflect the reproductive decline with age in normal women with proven fertility: a longitudinal study. Fertil Steril 83(4):979–987
Nelson SM, Yates RW, Fleming R (2007) Serum anti-Mullerian hormone and FSH: prediction of live birth and extremes of response in stimulated cycles—implications for individualization of therapy. Hum Reprod 22(9):2414–2421
Brodin T, Hadziosmanovic N, Berglund L, Olovsson M, Holte J (2013) Antimüllerian hormone levels are strongly associated with live-birth rates after assisted reproduction. J Clin Endocrinol Metab 98(3):1107–1114
Melo M et al (2010) A prospective, randomized, controlled trial comparing three different gonadotropin regimens in oocyte donors: ovarian response, in vitro fertilization outcome, and analysis of cost minimization. Fertil Steril 94(3):958–964
Lamazou F et al (2012) Cancellation of IVF-ET cycles: poor prognosis, poor responder, or variability of the response to controlled ovarian hyperstimulation? An analysis of 142 cancellations. J Gynecol Obstet Biol Reprod (Paris) 41(1):41–47
Irez T, Ocal P, Guralp O, Cetin M, Aydogan B, Sahmay S (2011) Different serum anti-Müllerian hormone concentrations are associated with oocyte quality, embryo development parameters and IVF-ICSI outcomes. Arch Gynecol Obstet 284:1295–1301
Baird DD, Steiner AZ (2012) Anti-müllerian hormone: a potential new tool in epidemiologic studies of female fecundability. Am J Epidemiol 175:245–249
Steiner AZ, Herring AH, Kesner JS, Meadows JW, Stanczyk FZ, Hoberman S et al (2011) Antimullerian hormone as a predictor of natural fecundability in women aged 30–42 years. Obstet Gynecol 1117:798–804
Fréour T, Mirallie S, Colombel A, Bach-Ngohou K, Masson D, Barriere P (2006) Anti-mullerian hormone: clinical relevance in assisted reproductive therapy. Ann Endocrinol 67:567–574
Check JH, Nazari P, Check ML, Choe JK, Liss JT (2002) Prognosis following in vitro fertilization-embryo transfer (IVF-ET) in patients with elevated day 2 or 3 serum follicle stimulating hormone (FSH) is better in younger vs older patients. Clin Exp Obstet Gynecol 29:42–44
Lin PX, Huang FJ, Kung FT, Chiang HJ, Lin YJ, Lin YC, Lan KC (2014) Evaluation of serum anti-müllerian hormone as a biomarker of early ovarian aging in young women undergoing IVF/ICS cycle. Int J Clin Exp Pathol 7(9):6245–6253
Lee JR, Liu CH, Huang CC, Hsieh KC, Lin PM, Lee MS et al (2009) Impact of female age and male infertility on ovarian reserve markers to predict outcome of assisted reproduction technology cycles. Reprod Biol Endocrinol 7:100
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
R. Gomez and M. Schorsch equally contributed to this work.
Rights and permissions
About this article
Cite this article
Gomez, R., Schorsch, M., Hahn, T. et al. The influence of AMH on IVF success. Arch Gynecol Obstet 293, 667–673 (2016). https://doi.org/10.1007/s00404-015-3901-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00404-015-3901-0